IPO
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
Cue Health went public on September 24 on the Nasdaq securities exchange under the ticker symbol HLTH.
Cognition Therapeutics, Pyxis Oncology and IsoPlexis Corp. all announced IPO plans.
Once the deal is done, the company will be renamed MoonLake Immunotherapeutics and trade on the Nasdaq under the ticker symbol MLTX.
This week, three global biopharmaceutical companies received over half a billion dollars to support research and development initiatives in the treatment of rare and deadly diseases.
Experts are predicting a record-breaking rush of IPOs this fall as companies flood to the Nasdaq.
Tyra Biosciences aspires to raise a $100 million IPO, according to its S-1 form filed with the U.S. Securities and Exchange commission late last week.
The global biopharmaceutical company said that it is well capitalized with cash, cash equivalents, restricted cash, and investments of as much as $222.8 million as of 30 June 2021.
Show me the money! This week’s who’s who of IPOs and financing rounds in the biopharma world.
Shares of Zymergen plummeted by 68% Tuesday from its April IPO price of $31 per share to just $11.7 per share after news that the company will not likely see revenue anytime soon.
PRESS RELEASES